Hepatitis E, what is the real issue?
acute viral hepatitis
chronic hepatitis
hepatitis E virus
neurologic symptoms
ribavirin
zoonosis
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
28
02
2021
accepted:
27
03
2021
pubmed:
12
5
2021
medline:
29
6
2021
entrez:
11
5
2021
Statut:
ppublish
Résumé
Hepatitis E virus (HEV) infection is a worldwide disease and the primary cause of acute viral hepatitis with an estimated 3.3 million symptomatic cases every year and 44,000 related deaths. It is a waterborne infection in the developing countries. In these countries, HEV genotypes 1 and 2 cause large outbreaks and affect young subjects resulting in significant mortality in pregnant women and patients with cirrhosis. In developed countries, HEV genotypes 3 and 4 are responsible for autochthonous, sporadic hepatitis and transmission is zoonotic. Parenteral transmission by the transfusion of blood products has been identified as a potential new mode of transmission. HEV can also cause neurological disorders and chronic infections in immunocompromised patients. The progression of acute hepatitis E is usually asymptomatic and resolves spontaneously. Diagnosis is based on both anti-HEV IgM antibodies in serum and viral RNA detection in blood or stools by PCR in immunocompetent patients, while only PCR is validated in immunocompromised individuals. Ribavirin is the only validated treatment in chronic infection. A vaccine has been developed in China.
Substances chimiques
Hepatitis Antibodies
0
Ribavirin
49717AWG6K
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
68-72Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Balayan MS, Andjaparidze AG, Savinskaya SS, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology. 1983;20(1):23-31.
Kamar N, Bendall R, Legrand-Abravanel F, et al. Hepatitis E. Lancet. 2012;379(9835):2477-2488.
Sridhar S, Yip CC-Y, Wu S, et al. Transmission of rat hepatitis E virus infection to humans in Hong Kong: a clinical and epidemiological analysis. Hepatology. 2021;73(1):10-22.
Smith DB, Izopet J, Nicot F, et al. Update: proposed reference sequences for subtypes of hepatitis E virus (species Orthohepevirus A). J Gen Virol. 2020;101(7):692-698.
Veronesi R, Morach M, Hübschke E, Bachofen C, Stephan R, Nüesch-Inderbinen M. Seroprevalence of hepatitis E virus in dogs in Switzerland. Zoonoses Public Health. 2021;68(1):8-11.
Lhomme S, Legrand-Abravanel F, Kamar N, Izopet J. Screening, diagnosis and risks associated with hepatitis E virus infection. Expert Rev Anti Infect Ther. 2019;17(6):403-418.
WHO. Hepatitis E: Fact Sheet. 2020. https://www.who.int/news-room/fact-sheets/detail/hepatitis-e
Jing W, Liu J, Liu M. The global trends and regional differences in incidence of HEV infection from 1990 to 2017 and implications for HEV prevention. Liver Int. 2021;41(1):58-69.
Khuroo MS, Kamili S, Jameel S. Vertical transmission of hepatitis E virus. Lancet. 1995;345(8956):1025-1026.
Kumar Acharya S, Kumar Sharma P, Singh R, et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol. 2007;46(3):387-394.
Gouilly J, Chen Q, Siewiera J, et al. Genotype specific pathogenicity of hepatitis E virus at the human maternal-fetal interface. Nat Commun. 2018;9(1):4748.
Mansuy JM, Abravanel F, Miedouge M, et al. Acute hepatitis E in south-west France over a 5-year period. J Clin Virol. 2009;44(1):74-77.
Dziedzinska R, Krzyzankova M, Bena M, Vasickova P. Evidence of Hepatitis E Virus in Goat and Sheep Milk. Viruses. 2020;12(12): https://doi.org/10.3390/v12121429
Hewitt PE, Ijaz S, Brailsford SR, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet. 2014;384(9956):1766-1773.
Gallian P, Couchouron A, Dupont I, et al. Comparison of hepatitis E virus nucleic acid test screening platforms and RNA prevalence in French blood donors. Transfusion. 2017;57(1):223-224. https://doi.org/10.1111/trf.13889
Gallian P, Pouchol E, Djoudi R, et al. Transfusion-transmitted hepatitis E virus infection in France. Transfus Med Rev. 2019;33(3):146-153.
Péron JM, Bureau C, Poirson H, et al. Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy. J Viral Hepat. 2007;14(5):298-303.
Izopet J, Tremeaux P, Marion O, et al. Hepatitis E virus infections in Europe. J Clin Virol. 2019;120:20-26.
Abravanel F, Pique J, Couturier E, et al. Acute hepatitis E in French patients and neurological manifestations. J Infect. 2018;77(3):220-226.
Sanabria-Cabrera J, Sanjuán-Jiménez R, Clavijo E, et al. Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry. Liver International. 2020;https://doi.org/10.1111/liv.14713
Drave SA, Debing Y, Walter S, et al. Extra-hepatic replication and infection of hepatitis E virus in neuronal-derived cells. J Viral Hepat. 2016;23(7):512-521.
van Eijk JJJ, Madden RG, van der Eijk AA, et al. Neuralgic amyotrophy and hepatitis E virus infection. Neurology. 2014;82(6):498-503.
Dartevel A, Colombe B, Bosseray A, et al. Hepatitis E and neuralgic amyotrophy: five cases and review of literature. J Clin Virol. 2015;69:156-164.
van Eijk JJJ, Dalton HR, Ripellino P, et al. Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy. Neurology. 2017;89(9):909-917.
van den Berg B, van der Eijk AA, Pas SD, et al. Guillain-Barré syndrome associated with preceding hepatitis E virus infection. Neurology. 2014;82(6):491-497.
Del Bello A, Guilbeau-Frugier C, Josse A-G, Rostaing L, Izopet J, Kamar N. Successful treatment of hepatitis E virus-associated cryoglobulinemic membranoproliferative glomerulonephritis with ribavirin. Transpl Infect Dis. 2015;17(2):279-283.
Panic N, Mihajlovic S, Vujasinovic M, Bulajic M, Löhr J-M. Pancreatitis associated with viral hepatitis: systematic review. J Clin Med. 2020;9(10): https://doi.org/10.3390/jcm9103309
Di Bartolomeo S, Carubbi F, Cipriani P. Hepatitis E virus and rheumatic diseases: what do rheumatologists need to know? BMC Rheumatol. 2020;4:51.
Tavitian S, Peron J-M, Huguet F, et al. Ribavirin for chronic hepatitis prevention among patients with hematologic malignancies. Emerg Infect Dis. 2015;21(8):1466-1469.
Ankcorn M, Said B, Morgan D, et al. Persistent hepatitis E virus infection across England and Wales 2009-2017: Demography, virology and outcomes. J Viral Hepatitis. 2021;28(2):420-430.
Legrand-Abravanel F, Kamar N, Sandres-Saune K, et al. Hepatitis E virus infection without reactivation in solid-organ transplant recipients. France. Emerg Infect Dis. 2011;17(1):30-37.
Kamar N, Selves J, Mansuy J-M, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358(8):811-817.
Abravanel F, Lhomme S, Chapuy-Regaud S, et al. Hepatitis E virus reinfections in solid-organ-transplant recipients can evolve into chronic infections. J Infect Dis. 2014;209(12):1900-1906.
Neukam K, Barreiro P, Macías J, et al. Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin. Clin Infect Dis. 2013;57(3):465-468.
Robbins A, Lambert D, Ehrhard F, et al. Severe acute hepatitis E in an HIV infected patient: successful treatment with ribavirin. J Clin Virol. 2014;60(4):422-423.
Pischke S, Peron J-M, von Wulffen M, et al. Chronic hepatitis E in rheumatology and internal medicine patients: a Retrospective Multicenter European Cohort Study. Viruses. 2019;11(2): https://doi.org/10.3390/v11020186
Baylis SA, Hanschmann K-M, Blümel J, Nübling CM, HEV Collaborative Study Group. Standardization of hepatitis E virus (HEV) nucleic acid amplification technique-based assays: an initial study to evaluate a panel of HEV strains and investigate laboratory performance. J Clin Microbiol. 2011;49(4):1234-1239.
Huang S, Zhang X, Jiang H, et al. Profile of acute infectious markers in sporadic hepatitis E. PLoS One. 2010;5(10):e13560.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol. 2018;68(6):1256-1271. Electronic address: easloffice@easloffice.eu.
Kamar N, Abravanel F, Behrendt P, et al. Ribavirin for hepatitis E virus infection after organ transplantation: a Large European Retrospective Multicenter Study. Clin Infect Dis. 2020;71(5):1204-1211.
Zhang J, Shih JW-K, Xia N-S. Long-term efficacy of a hepatitis E vaccine. N Engl J Med. 2015;372(23):2265-2266.